TB

2R2 Trial: High-Dose, Short-Duration Rifampicin for TB Prevention

Published in: The LancetAuthors: Ruslami R et al.Publication Year: 2024Source: The Lancet, DOI: 10.1016/S2213-2600(24)00076-6 Objective of the Study:The 2R2 Trial was conducted to compare the safety and treatment completion rates of different doses and durations of rifampicin in patients who … Read More